XL228

CAS No. 898280-07-4

XL228( —— )

Catalog No. M24922 CAS No. 898280-07-4

XL228 is an inhibitor of multi-targeted tyrosine kinase.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 106 In Stock
2MG 67 In Stock
5MG 96 In Stock
10MG 144 In Stock
25MG 257 In Stock
50MG 384 In Stock
100MG 570 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    XL228
  • Note
    Research use only, not for human use.
  • Brief Description
    XL228 is an inhibitor of multi-targeted tyrosine kinase.
  • Description
    XL228 is an inhibitor of multi-targeted tyrosine kinase (IC50s: 5, 3.1, 1.6, 6.1, 2 nM for Bcr-Abl, Aurora A, IGF-1R, Src, and Lyn, respectively).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    Bcr-Abl
  • Recptor
    Aurora A|Bcr-Abl|IGF-1R|Lyn|Src
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    898280-07-4
  • Formula Weight
    437.54
  • Molecular Formula
    C22H31N9O
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:83.33 mg/mL (190.45 mM)
  • SMILES
    CC(C)c1noc(CNc2nc(N3CCN(C)CC3)cc(Nc3n[nH]c(C4CC4)c3)n2)c1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Cortes J, et al. Preliminary Clinical Activity in a Phase I Trial of the BCR-ABL/IGF- 1R/Aurora Kinase Inhibitor XL228 in Patients with Ph++ Leukemias with Either Failure to Multiple TKI Therapies or with T315I Mutation. Blood 2008 112:3232
molnova catalog
related products
  • GNF-7

    A potent and selective type-II kinase inhibitor of Bcr-Abl.

  • N-Desmethyl imatinib

    N-Desmethyl imatinib is a metabolite of Imatinib, which is a multi-target inhibitor of c-Kit, v-Abl, and PDGFR.

  • AKE-72

    AKE-72 is a Pan-BCR-ABL inhibitor with anti-leukemic activity.AKE-72 inhibits the proliferation of Ba/F3 cells expressing natural BCR-ABL or its T315I mutant.